Activation and function of cyclin T–Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy

[1]  P. Kang,et al.  Akt/Protein Kinase B Promotes Organ Growth in Transgenic Mice , 2002, Molecular and Cellular Biology.

[2]  Michael D. Schneider,et al.  MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[3]  G. Orphanides,et al.  A Unified Theory of Gene Expression , 2002, Cell.

[4]  R. Behringer,et al.  Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK3 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  E. Olson,et al.  Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Maggioni,et al.  Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. , 2001, Journal of the American College of Cardiology.

[7]  Tamás Kiss,et al.  7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes , 2001, Nature.

[8]  Qiang Zhou,et al.  The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription , 2001, Nature.

[9]  S. Yusuf,et al.  Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril , 2001, Circulation.

[10]  B. Majello,et al.  Control of RNA polymerase II activity by dedicated CTD kinases and phosphatases. , 2001, Frontiers in bioscience : a journal and virtual library.

[11]  D. Price,et al.  Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo * , 2001, The Journal of Biological Chemistry.

[12]  M. Entman,et al.  Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Testa,et al.  Cyclin T2A Gene Maps on Human Chromosome 2q21 , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[14]  M. Mancini,et al.  The Cdk9 and cyclin T subunits of TAK/P-TEFb localize to splicing factor-rich nuclear speckle regions. , 2001, Journal of cell science.

[15]  R. Kitsis,et al.  The MEK1–ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice , 2000, The EMBO journal.

[16]  Junmin Peng,et al.  Tat Modifies the Activity of CDK9 To Phosphorylate Serine 5 of the RNA Polymerase II Carboxyl-Terminal Domain during Human Immunodeficiency Virus Type 1 Transcription , 2000, Molecular and Cellular Biology.

[17]  P. Kang,et al.  The conserved phosphoinositide 3‐kinase pathway determines heart size in mice , 2000, The EMBO journal.

[18]  G. Orphanides,et al.  FACT relieves DSIF/NELF-mediated inhibition of transcriptional elongation and reveals functional differences between P-TEFb and TFIIH. , 2000, Molecular cell.

[19]  Paul A. Overbeek,et al.  TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice , 2000, Nature Medicine.

[20]  J. Molkentin,et al.  Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Giordano,et al.  Physical interaction between CDK9 and B-Myb results in suppression of B-Myb gene autoregulation , 2000, Oncogene.

[22]  D. Reinberg,et al.  A protein phosphatase functions to recycle RNA polymerase II. , 1999, Genes & development.

[23]  E. Olson,et al.  Cardiac hypertrophy: sorting out the circuitry. , 1999, Current opinion in genetics & development.

[24]  R. Gaynor,et al.  Role of the human and murine cyclin T proteins in regulating HIV-1 tat-activation. , 1999, Journal of molecular biology.

[25]  Y. Hiroaki,et al.  Interactions of endothelin receptor subtypes A and B with Gi, Go, and Gq in reconstituted phospholipid vesicles. , 1999, Biochemistry.

[26]  B. Peterlin,et al.  Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b. , 1999, Virology.

[27]  Michael D. Schneider,et al.  A Ras-Dependent Pathway Regulates RNA Polymerase II Phosphorylation in Cardiac Myocytes: Implications for Cardiac Hypertrophy , 1998, Molecular and Cellular Biology.

[28]  John W. Adams,et al.  Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[30]  J. Milton,et al.  Identification of multiple cyclin subunits of human P-TEFb. , 1998, Genes & development.

[31]  R. Berezney,et al.  Growth-related Changes in Phosphorylation of Yeast RNA Polymerase II* , 1998, The Journal of Biological Chemistry.

[32]  M. Mathews,et al.  Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. , 1997, Genes & development.

[33]  G. Faye,et al.  Distinct activated and non‐activated RNA polymerase II complexes in yeast. , 1996, The EMBO journal.

[34]  M. Dahmus.  Reversible Phosphorylation of the C-terminal Domain of RNA Polymerase II* , 1996, The Journal of Biological Chemistry.

[35]  A. Rice,et al.  The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function , 1996, Journal of virology.

[36]  D. Morgan,et al.  Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase , 1994, Molecular and cellular biology.

[37]  J. Robbins,et al.  Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. , 1991, The Journal of biological chemistry.

[38]  Michael D. Schneider,et al.  Still stressed out but doing fine: normalization of wall stress is superfluous to maintaining cardiac function in chronic pressure overload. , 2002, Circulation.

[39]  W. Koch,et al.  Genetic Alterations That Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall Stress , 2002, Circulation.

[40]  Hiroshi Asanuma,et al.  Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy , 2002, Nature Medicine.

[41]  G. Dorn,et al.  Cytoplasmic signaling pathways that regulate cardiac hypertrophy. , 2001, Annual review of physiology.

[42]  W. MacLellan,et al.  Genetic dissection of cardiac growth control pathways. , 2000, Annual review of physiology.

[43]  G. Dorn,et al.  Gq signaling in cardiac adaptation and maladaptation. , 1999, Trends in cardiovascular medicine.

[44]  K. Kinzler,et al.  A simplified system for generating recombinant adenoviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Sadoshima,et al.  The cellular and molecular response of cardiac myocytes to mechanical stress. , 1997, Annual review of physiology.